Loading
HER2 drugs can weaken the heart's pumping, usually reversibly, so heart function is checked every three months during treatment.
Asymptomatic LVEF decline in 10-15% and symptomatic heart failure in 1-4% with trastuzumab, higher with prior or concurrent anthracyclines (NSABP B-31: 4.1% vs 0.8%). Mechanism: HER2 signalling maintains cardiomyocyte survival under stress. Management: hold for LVEF drop ≥16 points or below normal, ACE inhibitors/beta-blockers, rechallenge after recovery; anthracycline-free regimens (TCHP, T-DXd neoadjuvant) reduce risk.
Backbone ribbon from PDB 1N8Z. RCSB PDB 1N8Z. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Showing the molecule this term concerns: Trastuzumab.
Shares Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors, Heart function after anthracyclines, trastuzumab and chest radiotherapy, Cardio-oncology, Trastuzumab.
Shares Cardio-oncology, Trastuzumab, Survivorship and late effects are neglected, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares PERSEPHONE, Trastuzumab, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Pertuzumab, HER2-positive breast cancer.